BIOLIGHT(SZ:300246)2026-01-29 09:06Financial Performance Expectations - The company expects a net profit in the range of -80 million to -60 million CNY for the year 2025, indicating a decrease of 11.98% to an increase of 16.01% compared to the previous year[2][3]. - The expected net profit after deducting non-recurring losses is projected to be between -95 million and -68 million CNY, with a growth rate of 1.59% to 29.56% year-on-year[3]. - The company anticipates a non-recurring gain of approximately 8.07 million CNY, primarily from government subsidies, impacting the net profit positively[6]. Cost Management and Profitability - Despite an increase in product sales volume, the overall gross margin has declined due to competitive pricing pressures and rising raw material costs[5]. - The company has implemented cost control measures, resulting in a reduction of various expenses year-on-year, although foreign exchange losses and high amortization costs related to convertible bonds have negatively affected net profit[5]. - The company has made provisions for asset impairment on inventory and certain production equipment due to declining product sales prices, which will impact the net profit for the period[6]. Communication and Reporting - The company has communicated with the auditing firm regarding the performance forecast, and there are no discrepancies noted[4]. - The specific financial data for the 2025 fiscal year will be disclosed in the annual report, and any significant discrepancies will be reported in accordance with disclosure regulations[7].